Investigator

Sally N. Adebamowo

Professor · University of Maryland School of Medicine, Department of Epidemiology and Public Health

SNASally N. Adebamowo
Papers(3)
Different human papil…Association between S…Genome, HLA and polyg…
Collaborators(6)
Adebowale AdeyemoBrian BefanoCharles RotimiClement AdebamowoNicolas WentzensenNicole G Campos
Institutions(5)
U M Rogel Cancer Cent…National Human Genome…University Of Washing…Division Of Cancer Ep…Cuny Graduate School …

Papers

Different human papillomavirus types share early natural history transitions in immunocompetent women

AbstractNecessary stages of cervical carcinogenesis include acquisition of a carcinogenic human papillomavirus (HPV) type, persistence associated with the development of precancerous lesions, and invasion. Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS‐LSIL Triage Study (ALTS) and the Costa Rica HPV Vaccine Trial (CVT), we compared the early natural history of HPV types to inform transition probabilities for health decision models. We excluded women with evidence of high‐grade cervical abnormalities at any point during follow‐up and restricted the analysis to incident infections in all women and prevalent infections in young women (aged <30 years). We used survival approaches accounting for interval‐censoring to estimate the time to clearance distribution for 20 529 HPV infections (64% were incident and 51% were carcinogenic). Time to clearance was similar across HPV types and risk classes (HPV16, HPV18/45, HPV31/33/35/52/58, HPV 39/51/56/59 and noncarcinogenic HPV types); and by age group (18‐29, 30‐44 and 45‐54 years), among carcinogenic and noncarcinogenic infections. Similar time to clearance across HPV types suggests that relative prevalence can predict relative incidence. We confirmed that there was a uniform linear association between incident and prevalent infections for all HPV types within each study cohort. In the absence of progression to precancer, we observed similar time to clearance for incident infections across HPV types and risk classes. A singular clearance function for incident HPV infections has important implications for the refinement of microsimulation models used to evaluate the cost‐effectiveness of novel prevention technologies.

Association between Serum Folate and Vaginal High-Risk Human Papillomavirus Infections in United States Women

Serum concentration of folate was inversely associated with cervical intraepithelial neoplasia and cervical cancer in some studies. The association between folate and human papillomavirus (HPV) infection, a necessary cause of cervical cancer, has not been well elucidated. We evaluated whether serum folate concentrations were associated with high-risk HPV (hrHPV) infection. The study population was 11,801 females, aged 18-59 y, enrolled in the National Health and Nutrition Examination Survey (NHANES), from 2003 to 2016, in the United States. In this cross-sectional study, prevalence ratios (PRs) of vaginal hrHPV were calculated using logistic regression models, by quintiles of serum folate. Females in the lowest quintile had <21.3 nmol/L of folate. Approximately 23% of the females (2733/11,801) were hrHPV positive. In age-adjusted models, folate was significantly associated with hrHPV infection. The PRs and 95% confidence intervals (CIs) were (PR: 1.52; 95% CI: 1.37, 1.70) for the first, (PR: 1.29; 95% CI: 1.15, 1.44) for the second, (PR: 1.19; 95% CI: 1.06, 1.34) for the third, and (PR: 1.09; 95% CI: 0.96, 1.23) for the fourth quintiles, compared with the females in the highest quintile, with a significant P value for trend, <0.0001. The association remained statistically significant after the models were further adjusted for lifestyle and sexual risk factors for hrHPV infection; the females in the lowest quintile were more likely to have hrHPV infection than those in the highest quintile (PR: 1.40; 95% CI: 1.11, 1.53). Results from this sample of females in the United States suggest that serum folate concentration is inversely associated with hrHPV infection.

Genome, HLA and polygenic risk score analyses for prevalent and persistent cervical human papillomavirus (HPV) infections

AbstractGenetic variants that underlie susceptibility to cervical high-risk human papillomavirus (hrHPV) infections are largely unknown. We conducted discovery genome-wide association studies (GWAS), replication, meta-analysis and colocalization, generated polygenic risk scores (PRS) and examined the association of classical HLA alleles and cervical hrHPV infections in a cohort of over 10,000 women. We identified genome-wide significant variants for prevalent hrHPV around LDB2 and for persistent hrHPV near TPTE2, SMAD2, and CDH12, which code for proteins that are significantly expressed in the human endocervix. Genetic variants associated with persistent hrHPV are in genes enriched for the antigen processing and presentation gene set. HLA-DRB1*13:02, HLA-DQB1*05:02 and HLA-DRB1*03:01 were associated with increased risk, and HLA-DRB1*15:03 was associated with decreased risk of persistent hrHPV. The analyses of peptide binding predictions showed that HLA-DRB1 alleles that were positively associated with persistent hrHPV showed weaker binding with peptides derived from hrHPV proteins and vice versa. The PRS for persistent hrHPV with the best model fit, had a P-value threshold (PT) of 0.001 and a p-value of 0.06 (-log10(0.06) = 1.22). The findings of this study expand our understanding of genetic risk factors for hrHPV infection and persistence and highlight the roles of MHC class II molecules in hrHPV infection.

131Works
3Papers
6Collaborators

Positions

2025–

Professor

University of Maryland School of Medicine · Department of Epidemiology and Public Health

2021–

Associate Professor

University of Maryland School of Medicine · Department of Epidemiology and Public Health

2016–

Assistant Professor

University of Maryland School of Medicine · Department of Epidemiology and Public Health

2015–

Postdoctoral Research Fellow

National Human Genome Research Institute · Metabolic, Cardiovascular and Inflammatory Disease Branch

2014–

Postdoctoral Research Fellow

Harvard School of Public Health · Department of Nutrition

2011–

Predoctoral Research Fellow

Brigham and Women's Hospital/Harvard Medical School · Division of Preventive Medicine, Department of Medicine

Education

2014

Sc.D.

Harvard School of Public Health

2011

M.Sc.

University of London · London School of Hygiene and Tropical Medicine

2007

M.D.

University of Ibadan · College of Medicine

Country

US

Links & IDs
0000-0003-4713-2433

Scopus: 56669713900